Dose escalated radiotherapy alone or in combination with short-term androgen suppression for intermediate risk prostate cancer: outcomes from the NRG oncology …
DJ Krauss, TG Karrison, AA Martinez… - International Journal of …, 2021 - redjournal.org
Purpose/Objective (s) Androgen suppression can improve outcomes when added to
radiotherapy (RT) for intermediate risk prostate cancer, but no study to date has reported its
utility in the context of contemporary, dose-escalated RT. Herein, the clinical outcomes of a
phase III prospective trial evaluating the utility of total androgen suppression (TAS)
combined with dose-escalated RT for patients with intermediate risk prostate cancer are
reported. Materials/Methods Eligible patients had intermediate risk prostate cancer defined …
radiotherapy (RT) for intermediate risk prostate cancer, but no study to date has reported its
utility in the context of contemporary, dose-escalated RT. Herein, the clinical outcomes of a
phase III prospective trial evaluating the utility of total androgen suppression (TAS)
combined with dose-escalated RT for patients with intermediate risk prostate cancer are
reported. Materials/Methods Eligible patients had intermediate risk prostate cancer defined …